Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Rugo HS, O'Shaughnessy J, Boyle F, Toi M, Broom R, Blancas I, Gumus M, Yamashita T, Im YH, Rastogi P, Zagouri F, Song C, Campone M, San Antonio B, Shahir A, Hulstijn M, Brown J, Zimmermann A, Wei R, Johnston SRD, Reinisch M, Tolaney SM; monarchE Committee Members. Rugo HS, et al. Among authors: zagouri f. Ann Oncol. 2022 Jun;33(6):616-627. doi: 10.1016/j.annonc.2022.03.006. Epub 2022 Mar 23. Ann Oncol. 2022. PMID: 35337972 Free article.
Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.
Papadimitriou CA, Kalofonos H, Zagouri F, Papakostas P, Bozas G, Makatsoris T, Dimopoulos MA, Fountzilas G. Papadimitriou CA, et al. Among authors: zagouri f. Oncology. 2009;77(3-4):212-6. doi: 10.1159/000236021. Epub 2009 Sep 4. Oncology. 2009. PMID: 19729979 Clinical Trial.
Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA. Bamias A, et al. Among authors: zagouri f. Oncology. 2013;84(3):158-65. doi: 10.1159/000341366. Epub 2012 Dec 28. Oncology. 2013. PMID: 23296063
Pertuzumab in breast cancer: a systematic review.
Zagouri F, Sergentanis TN, Chrysikos D, Zografos CG, Filipits M, Bartsch R, Dimopoulos MA, Psaltopoulou T. Zagouri F, et al. Clin Breast Cancer. 2013 Oct;13(5):315-24. doi: 10.1016/j.clbc.2013.05.002. Epub 2013 Jun 27. Clin Breast Cancer. 2013. PMID: 23810292 Review.
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
Trillsch F, Mahner S, Hilpert F, Davies L, García-Martínez E, Kristensen G, Savarese A, Vuylsteke P, Los M, Zagouri F, Gladieff L, Sehouli J, Khoon Lee C, Gebski V, Pujade-Lauraine E. Trillsch F, et al. Among authors: zagouri f. Ann Oncol. 2016 Sep;27(9):1733-9. doi: 10.1093/annonc/mdw236. Epub 2016 Jun 10. Ann Oncol. 2016. PMID: 27287207 Free article. Clinical Trial.
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
Bamias A, Gibbs E, Khoon Lee C, Davies L, Dimopoulos M, Zagouri F, Veillard AS, Kosse J, Santaballa A, Mirza MR, Tabaro G, Vergote I, Bloemendal H, Lykka M, Floquet A, Gebski V, Pujade-Lauraine E. Bamias A, et al. Among authors: zagouri f. Ann Oncol. 2017 Aug 1;28(8):1842-1848. doi: 10.1093/annonc/mdx228. Ann Oncol. 2017. PMID: 28481967 Free article. Clinical Trial.
Cardiovascular toxicity of breast cancer treatment: an update.
Papageorgiou C, Andrikopoulou A, Dimopoulos MA, Zagouri F. Papageorgiou C, et al. Among authors: zagouri f. Cancer Chemother Pharmacol. 2021 Jul;88(1):15-24. doi: 10.1007/s00280-021-04254-w. Epub 2021 Apr 17. Cancer Chemother Pharmacol. 2021. PMID: 33864486 Review.
314 results